Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170645 | 1.00 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL30147114 | 1.00 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL4168491 | 1.00 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL14199081 | 0.89 | TAAR1 (0.56) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL27494557 | 0.87 | SLC6A3 (0.55) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL25200234 | 0.86 | CYP3A4 (0.55) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL19342841 | 0.86 | TAAR1 (0.66) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL25190561 | 0.86 | CYP3A4 (0.55) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| Machilin A SCHEMBL30678762 | 0.85 | TAAR1 (0.74) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| Machilin A SCHEMBL31237868 | 0.85 | TAAR1 (0.74) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119998433-A | Method for producing R-MDMA | 思维医学股份有限公司 | 2025-05-13 | — | — | CN | claimed |
| US-20240010628-A1 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2024-01-11 | — | — | US | claimed |
| EP-4551680-A2 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119998433-A | Method for producing R-MDMA | 思维医学股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20240010628-A1 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2024-01-11 | — | — | US | disclosed |
| WO-2024011067-A2 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20230150966-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150966-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES INC (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2023081897-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20090233913-A1 | OPTICAL ISOMERS OF DIHYDRO-2,3-BENZODIAZEPINES AND THEIR STEREOSELECTIVE SYNTHESIS | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2009-09-17 | — | — | US | disclosed |
| EP-1979308-A1 | OPTICAL ISOMERS OF DIHYDRO-2,3-BENZODIAZEPINES AND THEIR STEREOSELECTIVE SYNTHESIS | EGIS Gyógyszergyár Nyrt (HU) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007077469-A1 | OPTICAL ISOMERS OF DIHYDRO-2,3-BENZODIAZEPINES AND THEIR STEREOSELECTIVE SYNTHESIS | EGIS GYÓGYSZERGYÁR (HU) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233913-A1 | OPTICAL ISOMERS OF DIHYDRO-2,3-BENZODIAZEPINES AND THEIR STEREOSELECTIVE SYNTHESIS | GABRA2, GABRA3, GABRB2 | TAAR1 1606/4885SLC6A4 1543/4885SLC6A2 1275/4885 |
| US-20230150966-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | SLC6A3, DBH, PNMT | TAAR1 103/4885SLC6A4 12/4885SLC6A2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.